Compare Tango Therapeutics Inc. (TNGX) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $46.5 (market cap $318.07M). The key difference: Tango Therapeutics Inc. is far larger — about 11.8× Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for 49 Days on average.
| TNGX | USOI | |
|---|---|---|
Market Cap | $3.74B | $318.07M |
Volume | 3,438,781 | 104,534 |
Sector | Health | Income / Options Overlay |
52-Week High | $32.90 | $61.17 |
52-Week Low | $7.50 | $42.27 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
USOI trades at $46.38 with a modest 0.29% daily gain, showing bullish technical momentum with strong moving average signals. The stock lacks traditional fundamental metrics as it's an ETN tracking credit-linked notes, not a conventional company. Recent technical indicators show mixed signals with neutral oscillators but strong trend strength. Support levels cluster around $45-46 with resistance at $46-47, indicating tight trading range dynamics.
As a structured product, USOI offers exposure to credit markets but carries unique risks including issuer credit risk and complex payout structures. The bullish technical setup suggests near-term upside potential, though investors must understand the instrument's specialized nature and sensitivity to credit market conditions rather than traditional equity fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
